WallStreetZenWallStreetZen

NASDAQ: PETS
Petmed Express Inc Stock Forecast, Predictions & Price Target

Analyst price target for PETS

Based on 1 analyst offering 12 month price targets for Petmed Express Inc.
Min Forecast
$6.50+58.15%
Avg Forecast
$6.50+58.15%
Max Forecast
$6.50+58.15%

Should I buy or sell PETS stock?

Based on 1 analyst offering ratings for Petmed Express Inc.
Strong Sell
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
1 analysts 100%

Be the first to know when Wall Street analysts revise their PETS stock forecasts and price targets.

PETS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-16

1 of 1

Forecast return on equity

Is PETS forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
20.1%

Forecast return on assets

Is PETS forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

PETS revenue forecast

What is PETS's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$315.7M+14%
Avg 2 year Forecast
$324.9M+17.3%
PETS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

PETS revenue growth forecast

How is PETS forecast to perform vs Pharmaceutical Retailers companies and vs the US market?
Company
8.3%
Industry
2.45%
Market
9.39%
PETS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
PETS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

PETS vs Pharmaceutical Retailer Stocks

TickerPricePrice TargetUp/downsideConsensus
PETS$4.11$6.50+58.15%Strong Sell
YI$1.00N/AN/A
BIMI$1.34N/AN/A
MEDS$6.93N/AN/A
LFLY$2.22$6.00+170.27%Strong Buy

Petmed Express Stock Forecast FAQ

Is Petmed Express Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: PETS) stock is to Strong Sell PETS stock.

Out of 1 analyst, 0 (0%) are recommending PETS as a Strong Buy, 0 (0%) are recommending PETS as a Buy, 0 (0%) are recommending PETS as a Hold, 0 (0%) are recommending PETS as a Sell, and 1 (100%) are recommending PETS as a Strong Sell.

If you're new to stock investing, here's how to buy Petmed Express stock.

What is PETS's revenue growth forecast for 2025-2026?

(NASDAQ: PETS) Petmed Express's forecast annual revenue growth rate of 8.3% is forecast to beat the US Pharmaceutical Retailers industry's average forecast revenue growth rate of 2.45%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.39%.

Petmed Express's revenue in 2024 is $276,967,000.On average, 1 Wall Street analysts forecast PETS's revenue for 2025 to be $6,677,255,376, with the lowest PETS revenue forecast at $6,677,255,376, and the highest PETS revenue forecast at $6,677,255,376.

In 2026, PETS is forecast to generate $6,870,765,908 in revenue, with the lowest revenue forecast at $6,870,765,908 and the highest revenue forecast at $6,870,765,908.

What is PETS's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: PETS) forecast ROA is N/A, which is lower than the forecast US Pharmaceutical Retailers industry average of N/A.

What is PETS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year PETS price target, the average PETS price target is $6.50, with the highest PETS stock price forecast at $6.50 and the lowest PETS stock price forecast at $6.50.

The Wall Street analyst predicted that Petmed Express's share price could reach $6.50 by Nov 16, 2024. The average Petmed Express stock price prediction forecasts a potential upside of 58.15% from the current PETS share price of $4.11.

What is PETS's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: PETS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.